Quarterly ResultApr 30, 2026, 07:07 AM
LLY Q1 Revenue +56% to $19.8B; EPS $8.26; Raises FY Guidance
AI Summary
Eli Lilly and Company reported strong first-quarter 2026 financial results, with revenue increasing 56% to $19.8 billion and reported EPS rising 170% to $8.26. The company raised its full-year 2026 revenue guidance to a range of $82.0 billion to $85.0 billion and non-GAAP EPS guidance to $35.50 to $37.00. Key drivers included significant volume growth from new medicines like Mounjaro and Zepbound, alongside the U.S. FDA approval of Foundayo for obesity. Lilly also highlighted pipeline progress and strategic business development with four acquisitions.
Key Highlights
- Q1 2026 revenue increased 56% to $19.8 billion.
- Q1 2026 reported EPS rose 170% to $8.26.
- Raised full-year 2026 revenue guidance to $82.0B-$85.0B.
- Raised full-year 2026 non-GAAP EPS guidance to $35.50-$37.00.
- U.S. FDA approved Foundayo (orforglipron) for adults with obesity.
- Mounjaro Q1 revenue increased 125% to $8.7 billion.
- U.S. Zepbound Q1 revenue increased 79% to $4.1 billion.
- Agreed to acquire Orna, Centessa, Kelonia, and Ajax Therapeutics.